Introduction {#s1}
============

Auditory verbal hallucinations (AVH) are voices perceived during wakefulness, in the absence of an external origin ([@B9]). The highest prevalence of these phenomena is in patients diagnosed with schizophrenia \[i.e., 70--80%, ([@B10])\]. In these patients they tend to also yield high levels of distress which may lead to destructive behavior, such as suicide and homicide ([@B11], [@B12]). Although less well-known, AVH are experienced in the context of borderline personality disorder (BPD) as well ([@B10], [@B13], [@B14]). BPD is a severe psychiatric disorder with a lifetime prevalence rate of 1--3% in the general population ([@B15], [@B16]). It is conceptualized as an emotion-regulation disorder ([@B17]), characterized by unstable relationships, identity disturbances, and self-destructive behavior. Comorbidity with depression and other psychiatric disorders is high ([@B18]). AVH experienced by patients with BPD have long been characterized as "pseudohallucinations," since they were thought to be mild and phenomenologically different from those in schizophrenia ([@B19]). This line of thought is still reflected in the operational criteria for BPD featuring in the fifth edition of the *Diagnostic and Statistical Manual of Mental Disorders* \[DSM-5; ([@B20])\], which states that, "*Some individuals develop psychotic-like symptoms (e.g., hallucinations, body-image distortions, ideas of reference, hypnagogic phenomena) during times of stress*." However, valid definitions for terms like "pseudohallucination" and "psychotic-like" symptoms are lacking ([@B9]).

Furthermore, there are indications that AVH are frequent and severe in the context of BPD, and that their phenomenological characteristics do not differ essentially from those of AVH in patients diagnosed with schizophrenia ([@B2]). Therefore, we prefer to regard AVH in patients with BPD as genuine hallucinations.

Rationale
---------

Because of the burden caused by AVH in the context of BPD, and the ensuing risk of hospitalization and an unfavorable outcome, there is an urgent need for effective treatment of these perceptual phenomena ([@B21], [@B22]).

Objective
---------

Since therapeutic guidelines for this specific purpose are lacking, this study aims to present a systematic review of the literature on AVH in BPD, with special focus on the efficacy of treatment for psychotic symptoms in this patient group. Therefore, the aim of this study was to answer the following questions in patients with BPD:

1.  What is the prevalence of AVH?

2.  What are the phenomenological characteristics and severity of AVH?

3.  What is the association between AVH and comorbid disorders and childhood trauma?

4.  What is the efficacy of treatment of psychotic symptoms?

Methods {#s2}
=======

Study design
------------

A systematic review was conducted of studies reporting on the treatment of AVH and other psychotic symptoms in the context of BPD.

Search strategy
---------------

A systematic search was performed using the PubMed and Ovid databases from 1806 through April 2017 (Medline 1946-, Embase 1974-, PsycINFO 1806-, Cochrane DSR, ACP, Journal Club, DARE, CCTR, CMR, HTA, NHSEED).

The following search terms were used: hallucination, auditory hallucination, auditory verbal hallucination, delusions, hallucinations, acute psychosis, childhood psychosis, hallucinosis, "paranoia (psychosis)," schizophrenia, affective psychosis/ or alcoholic psychosis/ or reactive psychosis/ or toxic psychoses, borderline state, "fragmentation (schizophrenia)," psychoticism, schizophreniform disorder, schizotypy," positive and negative symptoms," paranoid schizophrenia, undifferentiated schizophrenia, antipsychotic (drugs/agents), neuroleptic (drugs/agents), cognitive-behavioral therapy, behavior therapy, cognitive therapy, brain stimulation, direct-current stimulation, transcranial magnetic stimulation, clinical study, and borderline personality disorder.

Data sources, studies selections, and data extraction
-----------------------------------------------------

Articles were considered eligible for inclusion when they were written in English and presented original data *either* regarding auditory (verbal) hallucinations in patients with a primary diagnosis of BPD, *or* regarding the efficacy of antipsychotics, cognitive-behavioral therapy (CBT), non-invasive brain stimulation or the effects on treatment on the severity of (specific) psychotic symptoms in patients with BPD. The rationale to explore these interventions is that the first treatment option for hallucinations in schizophrenia spectrum disorders is antipsychotic medication, which can induce a rapid decrease in severity ([@B23]). CBT can be applied as an augmentation to antipsychotic medication, thereby reducing anxiety and distress. Transcranial magnetic stimulation (TMS) is an experimental treatment method aimed at reducing the frequency and severity of auditory hallucinations.

Cross references were systematically assessed and checked via *Google Scholar*.

Data analysis
-------------

Mean weighted prevalence rates were computed using SPSS version 23.0. The total number of patients with AVH was divided by the total number of patients who participated into the studies presenting prevalence rates.

The severity of other psychotic symptoms was explored in a population of 107 outpatients with BPD with and without hallucinations ([@B14]). In that study, the presence of hallucinations was associated with the presence of delusions, but not with negative symptoms and disorganization. For the present review, additional analyses were performed to investigate comorbid psychotic symptoms in patients with BPD with and without AVH (*n* = 101). For this, patients were divided into two groups: (i) patients with AVH occurring at least weekly, and (ii) patients with less frequent AVH or no AVH at all.

To investigate an association between AVH and comorbid disorders and childhood trauma, we repeated the analyses (in which associations between hallucinations and the number of comorbid psychiatric disorders, and PTSD and emotional abuse were established) of the study by Niemantsverdriet et al. ([@B14]) for BPD patients with and without AVH. For this, a logistic regression with backward selection was used to examine the association between AVH and specific comorbid psychiatric disorders. These disorders were clustered into three groups, i.e., mood disorders (unipolar depression, bipolar I and II disorder), post-traumatic stress disorder (PTSD), and substance use disorders (i.e., alcohol abuse and dependence, drug abuse and dependence, or both).

Furthermore, we used a proportional odds model with backward selection to study the association between AVH and five subtypes of childhood trauma.

Results {#s3}
=======

The literature search yielded 569 publications on AVH and/or the use of antipsychotics in patients with BPD. Of these, 36 studies (with a total of 1,263 patients) were potentially eligible for this systematic review. Thirty-six studies were considered eligible for inclusion: 15 on AVH (with a total of 677 patients) and 22 on the treatment of psychotic features. One study was included in both systematic reviews. Of the latter 22 studies, 21 assessed the efficacy of antipsychotic medications in a total of 572 patients. Reasons for exclusion are described in Figure [1](#F1){ref-type="fig"}. An overview of the included studies is presented in Table [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}. In one study, the efficacy of combined early intervention for BPD and specialized first-episode psychosis treatment was explored ([@B54]).

![Flowchart of literature search on borderline personality disorder, auditory verbal hallucinations and antipsychotics.](fpsyt-09-00347-g0001){#F1}

###### 

Studies included in the present review (*n* = 15).

  **Study**                          **(*n*)**                                 **In/outpatients**    **Diagnostic instrument**   **AVH instrument**                                                                                                                                                                                                                    **Other instruments**                           **Prevalence A(V)H**                   **Comments**
  ---------------------------------- ----------------------------------------- --------------------- --------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- -------------------------------------- --------------------------------------------------------------------
  Lotterman ([@B24])                 8 females                                 Inpatients            --                          --                                                                                                                                                                                                                                    --                                              NA                                     Case report
  Chopra and Beatson ([@B25])        13 (85% female)                           Inpatients            DIBP                        DIBP                                                                                                                                                                                                                                  --                                              Point prevalence AH 54%                
  George and Soloff ([@B26])         24 (77% female)                           Inpatients            DIB                         SSI, Meehl scale                                                                                                                                                                                                                      --                                              AH 21%                                 
  Suzuki et al. ([@B27])             5 females                                 Inpatients            DSM IV                      --                                                                                                                                                                                                                                    --                                              NA                                     Case report
  Yee et al. ([@B19])                171 (90% female)                          Outpatients           DIB-R                       SCL-90                                                                                                                                                                                                                                DES, SCID-D, McGuffin\'s Opcrit Questionnaire   Point prevalence 29%                   
  Barnow et al. ([@B28])             1 female                                  Inpatient             --                          --                                                                                                                                                                                                                                    --                                              NA                                     Case report
  Kingdon et al. ([@B29])            33 (76% female)                           In- and outpatients   SCID II                     PSYRATS                                                                                                                                                                                                                               CTQ                                             Point prevalence 46%                   Versus schizophrenia
  Adams and Sanders ([@B30])         7 (86% female)                            Outpatients           --                          PSYRATS, PSE                                                                                                                                                                                                                          --                                              NA                                     Case report
  Slotema et al. ([@B2])             38 females                                Outpatients           SCID II                     PSYRATS                                                                                                                                                                                                                               --                                              NA                                     Versus schizophrenia and individuals without psychiatric diagnoses
  Hepworth et al. ([@B31])           22 (60% female)                           In- and outpatients   SCID II                     PSYRATS                                                                                                                                                                                                                               SCID I, BAVQ                                    NA                                     Versus schizophrenia Overlap with ([@B29])
  Pearse et al. ([@B32])             30 (90% female)                           Outpatients           DSM IV                      PSE                                                                                                                                                                                                                                   --                                              Lifetime prevalence 50%                
  Tschoeke et al. ([@B33])           23 females                                Inpatients            DSM IV-TR                   PANSS                                                                                                                                                                                                                                 NA                                              NA                                     Versus schizophrenia patients
  Slotema et al. ([@B22])            89 (92% female)                           Outpatients           SCID II                     PSYRATS                                                                                                                                                                                                                               MINI plus, hospitalization                      See Niemantsverdriet et al. ([@B14])   Overlap with ([@B14])
  Niemantsverdriet et al. ([@B14])   324, subgroup 107 patients (93% female)   Outpatients           DSM IV-TR                   Tailor-made interview by asking if the patient ever heard/saw/tasted/ smelled or felt something that other people did not perceive, or for which they had no explanation, including frequency and content, subgroup: PANSS, PSYRATS   MINI Plus, CTQ                                  Point prevalence AH 27%, AVH 21%       
  Slotema et al. ([@B21])            38 females                                Outpatients           SCID II                     PSYRATS                                                                                                                                                                                                                               BAVQ, SCRS, VPDS                                NA                                     Overlap with ([@B14])

*AH, auditory hallucinations; AVH, auditory verbal hallucinations; BAVQ, Beliefs About Voices Questionnaire; CTQ, Childhood Trauma Questionnaire; DES, Dissociative Experience Scale; DIB-R, Diagnostic Interview for Borderlines Revised; DIBP, Diagnostic Interview for Borderline Patients; MINI Plus, Mini International Neuropsychiatric Interview Plus; NA, not applicable; PANSS, Positive And Negative Syndrome Scale; PSE, Present State Examination; PSYRATS, Psychotic Symptom Rating Scales; SCID II, Structured Clinical Interview for DSM IV axis 2 Personality Disorders; SCID-D, Structured Clinical Interview for DSM IV dissociative disorders; SCL-90, Symptom Check List 90 items; SCRS, Social Comparison Rating Scale; SSI, Schizotypal Symptom Inventory; VPDS, Voice Power Differential Scale*.

###### 

Borderline personality disorder (BPD) and antipsychotics for severity of psychotic symptoms.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                           **Design**           **Active (*n*)**   **Placebo/ control (*n*)**   **Antipsychotic**                             **Dosage mean equivalent haloperidol**   **Instrument**                              **Effect**   **Notification**
  ----------------------------------- -------------------- ------------------ ---------------------------- --------------------------------------------- ---------------------------------------- ------------------------------------------- ------------ --------------------------------------------------------------------------------------------------------
  Serban and\                         RCT                  26                 26                           Thiothixene vs.\                              2.8 mg\                                  PAI\                                        \+           BPD 31%, SPD\
  Siegel ([@B34])                                                                                          haloperidol                                   3 mg                                     Paranoid ideation                                        27% or mixed 31% thiothixene superior to haloperidol Mild transient psychotic episode before admission

  Goldberg et al. ([@B35])            RCT\                 24                 26                           Thiothixene\                                  2.6 mg                                   HSCL-90 Anger-hostility psychotic SIB\      --\          BPD 34%, SPD 26% or mixed 40% and at least one psychotic symptom
                                      placebo                                                              12 weeks                                                                               Ideas of reference\                         +\           
                                                                                                                                                                                                  Paranoid ideation\                          --\          
                                                                                                                                                                                                  Delusions/hallucinations\                   --\          
                                                                                                                                                                                                  Psychotic symptoms                          --           

  Soloff et al. ([@B36])              RCT\                 28                 28                           Haloperidol\                                  4.8 mg                                   SCL-90\                                     \+           BPD 39%, SPD 4%, or mixed 57%, vs. amitriptyline vs. placebo
                                      placebo                                                              6 weeks                                                                                Paranoid ideation                                        

  Soloff et al. ([@B37])              RCT\                 36                 34                           Haloperidol\                                  3.9 mg                                   SCL-90 Paranoid ideation\                   --\          BPD with or without SPD vs. phenelzine
                                      placebo                                                              5 weeks                                                                                IMPS Paranoid ideation                      --           

  Zanarini and Frankenburg ([@B38])   RCT placebo          19                 9                            Olanzapine\                                   4 mg                                     SCL-90\                                     \+           
                                                                                                           6 months                                                                               Paranoid ideation                                        

  Nickel et al. ([@B39])              RCT\                 26                 26                           Aripiprazole\                                 7.5 mg                                   SCL-90\                                     \+           
                                      placebo                                                              8 weeks                                                                                Paranoid ideation                                        

  Pascual et al. ([@B40])             RCT\                 30                 30                           Ziprasidone\                                  5.3 mg                                   BPRS Psychotic symptoms\                    --\          
                                      placebo                                                              12 weeks                                                                               Hallucinations\                             --\          
                                                                                                                                                                                                  CGI-BPD\                                    --\          
                                                                                                                                                                                                  Paranoid ideation                           --           

  Shafti and Shahveisi ([@B41])       RCT                  14                 14                           Haloperidol vs olanzapine\                    7.1 mg\                                  BPRS Psychotic symptoms\                    --\          
                                                                                                           8 weeks                                       5.1 mg                                   Paranoid ideation                           +            

  Shafti and Kaviani ([@B42])         RCT                  12                 12                           Olanzapine vs aripiprazole\                   4.8mg\                                   BPRS\                                       \+           Significant for aripiprazole, not for olanzapine
                                                                                                           8 weeks                                       3.5 mg                                   Paranoid ideation                                        

  Teicher et al. ([@B43])             Open label           12                                              Thioridazine\                                 2.3 mg                                   SCL-90\                                     --           
                                                                                                           12 weeks                                                                               Paranoid ideation                                        

  Frankenburg and Zanarini ([@B44])   Cases rerated        15                                              Clozapine\                                    6.3 mg                                   BPRS\                                       \+\          Treatment-resistant psychotic patients, 47% also SPD, all patients severe abuse during childhood
                                                                                                           2-9 months                                                                             Psychotic symptoms\                         +\           
                                                                                                                                                                                                  Paranoid ideation\                          +            
                                                                                                                                                                                                  Hallucinations                                           

  Suzuki et al. ([@B27])              Case series          2                                               Antipsychotic deposit injection haloperidol   9-18 mg                                  Auditory (verbal) hallucinations\           \+\          
                                                                                                                                                                                                  Delusions and hallucinations                +            

  Benedetti et al. ([@B45])           Open label           12                                              Clozapine\                                    1.1 mg                                   BPRS\                                       \+           With severe psychotic-like symptoms
                                                                                                           16 weeks                                                                               Psychotic symptoms                                       

  Schulz et al. ([@B46])              Open label           11                                              Olanzapine\                                   5.8 mg                                   BPRS\                                       \+\          
                                                                                                           8 weeks                                                                                Psychotic symptoms\                         +            
                                                                                                                                                                                                  SCL-90 Paranoid ideation                                 

  Rocca et al. ([@B47])               Open label           15                                              Risperidone\                                  5 mg                                     BPRS\                                       \+           
                                                                                                           8 weeks                                                                                Paranoid ideation                                        

  Pascual et al. ([@B48])             Open label           12                                              Ziprasidone\                                  6.4 mg                                   BPRS\                                       \+\          
                                                                                                           2 weeks                                                                                Psychotic symptoms\                         +            
                                                                                                                                                                                                  SCL-90-R Paranoid ideation                               

  Mobascher et al. ([@B49])           Cases                3                                               Aripiprazole up to 9 weeks                    5-12.5 mg                                Psychotic symptoms                          \+           

  Perella et al. ([@B50])             Open label           29                                              Quetiapine\                                   10.1 mg                                  BPRS\                                       \+           
                                                                                                           12 weeks                                                                               Paranoid ideation                                        

  Mauri et al. ([@B51])               Naturalistic study   13                                              Quetiapine\                                   10.4 mg                                  PANSS positive items                        \+           Compared to patients with schizophrenia and drug-induced psychosis
                                                                                                           2 weeks                                                                                                                                         

  Anjee et al. ([@B52])               Open label           16                                              Quetiapine\                                   10.1 mg                                  SCL-90 Paranoid ideation\                   \+\          
                                                                                                           8 weeks                                                                                SIB Ideas of reference Paranoid ideation\   +\           
                                                                                                                                                                                                  Delusions/hallucinations                    +\           
                                                                                                                                                                                                                                              +            

  Martin-Bianco et al. ([@B53])       Open label           12                                              Asenapine 8 weeks                             5.8 mg                                   CGI-BPD Paranoid ideation                   −            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*BPRS, Brief Psychiatric Rating Scale; CGI-BPD, Clinical Global Impression for Borderline Personality Disorder; HSCL-90, Hopkins Symptom Checklist 90; IMPS, Inpatients Multidimensional Psychiatric Scale; PANSS pos, Positive And Negative Syndrome Scale positive items; RCT, randomised controlled trial; SCL-90, Symptom Checklist 90; SIB, Schedule for Interviewing Borderlines; SIB, Schedule for Interviewing Borderlines; SPD, schizotypal personality disorder*.

Prevalence rates of AVH
-----------------------

Of the 15 studies on AVH, six studies reported the prevalence rates for auditory hallucinations and AVH in 21--46% of the patients, the mean weighted point prevalence of AVH was 25% ([@B14], [@B19], [@B29]). With the exception of some patients in the study of Kingdon et al. ([@B29]), all study populations consisted of *outpatients*. For outpatients, the mean weighted point prevalence of AVH was 24%. In two patient samples of up to 37 *hospitalized* patients, the prevalence of auditory hallucinations ranged from 21 to 38% ([@B25], [@B26]) with a mean weighted prevalence of **27%**. The lifetime prevalence for auditory hallucinations was **50%** ([@B32]).

Phenomenology and severity of AVH
---------------------------------

In the studies in this review, the mean frequency of AVH in BPD ranged from once per day to once per hour, with each episode lasting several minutes or more ([@B2], [@B14], [@B29]). The mean onset of AVH was reported to be up to 18 years previously ([@B2], [@B14], [@B19], [@B32]). About half of the patients reported more than one voice ([@B19], [@B32]), speaking in the second person and, sometimes, in the third person ([@B32]). These voices were experienced as "comments" by 61% of the patients and as "dialogues" by 40% ([@B33]); in addition, 56% experienced imperative hallucinations ([@B21]). Control over the voices was virtually absent ([@B2], [@B14], [@B19], [@B29]). In four case reports (describing seven outpatients and nine inpatients), 75% were criticized by their voices, whereas commands (e.g., to hurt themselves) were perceived by 50% ([@B24], [@B27], [@B28], [@B30]). The duration of experiencing episodes with AVH ranged from several days to many years ([@B24], [@B27], [@B28], [@B30]). Voices are present, in particular, during times of stress ([@B24], [@B27], [@B30]). Compared to individuals with AVH without a psychiatric disorder, patients with BPD and AVH tend to show much higher scores on the majority of items on AVH questionnaires \[e.g., "frequency," "duration," and "controllability"; ([@B2])\]. Regarding the phenomenological characteristics of AVH in BPD, no differences were found compared to those reported in schizophrenia ([@B2], [@B29], [@B32], [@B33])\].

The content of voices in BPD tends to be negative and critical ([@B2], [@B14], [@B19], [@B29]). Compared to patients with schizophrenia, the ensuing distress was equal to or even higher in patients with BPD ([@B2], [@B29]). This is in marked contrast with AVH experienced by individuals without a psychiatric diagnosis, which tend to be less frequent, mild and often benevolent ([@B2]). Two studies explored beliefs about voices ([@B21], [@B31]). In 10 patients with BPD, in 23 with schizophrenia and in 12 patients with both disorders, no substantial differences were found regarding beliefs about the power and malevolent intent of the participants\' dominant voices ([@B31]); in all groups, the scores on these items were high. The majority of a sample of 38 patients with BPD with AVH rated their voices as malevolent and omnipotent, as well as higher in social rank than themselves ([@B21]).

The risks for suicidal attempts and hospitalization, associated with AVH, were explored in a sample of 27 outpatients with BPD and AVH, and in 62 without AVH ([@B22]). The presence of AVH was associated with a significantly higher incidence of suicidal plans and attempts in the month prior to study participation, a greater number of hospitalizations, and a shorter interval until hospitalization. In the latter study, the Psychotic Symptom Rating Scales (PSYRATS) was used as an outcome measure ([@B55]). All subscales of the PSYRATS showed a positive correlation with suicide plans. The phenomenological subscale and the subscale for distress due to AVH also showed a positive correlation with suicide attempts. Moreover, higher scores for distress due to AVH were associated with more frequent hospital admissions.

The severity of other psychotic symptoms was explored in a population of 107 outpatients with BPD with and without hallucinations ([@B14]). For the present review, additional analyses were performed to investigate comorbid psychotic symptoms in patients with and without AVH (*n* = 101). Of the 28 hallucinating patients, 78% experienced AVH at least once per day, 79% experienced at least one hallucination in a different sensory modality (i.e., visual, tactile, olfactory or gustatory), and 61% experienced additional hallucinations in multiple sensory modalities. Among patients with AVH, delusions were present in 44% of the cases, hallucinatory behavior in 70%, and suspiciousness and/or ideas of persecution in 33%.

In another study, the severity of positive symptoms in patients with BPD who experienced AVH was compared to that in patients with schizophrenia and AVH ([@B33]). In the year prior to study inclusion, in 23 patients with schizophrenia and in 21 patients with BPD, the scores for most items on the Positive and Negative Syndrome Scale ([@B56]), i.e., delusions, conceptual disorganization, grandiosity, and negative symptoms, were higher for the schizophrenia group. Scores for BPD were the same as found in the present study.

In a case series of 10 patients with BPD, Yee et al. ([@B19]) explored the co-occurrence of hallucinations in various sensory modalities. In their group, 30% experienced visual and olfactory hallucinations in addition to their AVH, while all of them (100%) reported thought insertion, 90% thought blocking or withdrawal, and 70% the sensation of being under the influence of some external power. In four other case reports (describing a total of 16 patients), AVH were regularly accompanied by visual, olfactory, and tactile hallucinations, as well as by paranoid delusions. In addition, one patient experienced ideas of reference ([@B24], [@B27], [@B28], [@B30]).

Comorbid disorders and childhood trauma
---------------------------------------

Very few studies have investigated the association between AVH and comorbid psychiatric disorders. Tschoeke et al. ([@B33]) explored childhood abuse and dissociative disorders in 23 BPD patients with AVH, and in 21 patients with schizophrenia. The BPD patients more frequently reported childhood trauma, notably emotional abuse and neglect. Moreover, the BPD patients scored higher than the schizophrenia patients on scales for emotional and physical abuse and neglect, and on scales for sexual abuse. Major dissociative disorders were present in 96% of the BPD patients (78% dissociative disorder not otherwise specified, and 18% dissociative identity disorder), whereas they were absent in patients diagnosed with schizophrenia. We repeated the analyses of the study by Niemantsverdriet et al. ([@B14]) for BPD patients with and without AVH. A best fit was achieved by including PTSD and excluding mood disorders and substance use disorders. For patients with PTSD, the odds ratio (OR) for experiencing AVH, as compared to patients without PTSD, was 2.7 (CI 1.2--7.2, *p* = 0.021). No significant associations were found between the presence of AVH and comorbid mood or substance-use disorders. In addition, our analyses showed that the median number of comorbid diagnoses was higher for BPD patient with AVH than for those without (four vs. three, respectively; Kendall\'s tau-b 0.199, *p* = 0.021). In addition, a best fit was achieved for emotional abuse by dropping the variables for the other four subtypes, i.e., sexual abuse, physical abuse, and physical, and emotional neglect. The OR for emotional abuse was 1.1 (CI 1.014--1.220, *p* = 0.024).

Treatment of psychotic symptoms in patients with BPD
----------------------------------------------------

Our search yielded 21 studies on treatment with antipsychotics in BPD, describing a total of 572 patients (Table [2](#T2){ref-type="table"}).

We found no comparable studies in the field of CBT or non-invasive brain stimulation, i.e., transcranial direct current stimulation (tDCS) and TMS. However, Gleeson et al. ([@B54]) reported on a randomized controlled pilot study with 16 patients (aged 15--25 years) in which they compared combined specialist first-episode treatment plus specialist early intervention for borderline personality, entitled Helping Young People Early (HYPE; using an integrated, team-based intervention model comprising time-limited cognitive-analytic therapy, case management, and general psychiatric care) with specialist first-episode treatment (SFET) alone (2012). Their aim was to provide treatment for both psychosis and borderline personality. Although the numbers were too small to allow for significance testing or the calculation of effect sizes, the HYPE + SFET group showed fewer positive psychotic and negative symptoms, less severe anhedonia and depression, better functioning, and better adherence to medication than the SFET group. However, a larger randomized controlled trial (RCT) is needed to confirm these results.

In four studies describing antipsychotic treatment for patients with BPD *and* psychotic features/disorders ([@B34], [@B35], [@B44], [@B45]), one included only treatment-resistant psychotic patients with BPD, which were subsequently recruited for a larger study on the efficacy of clozapine for treatment-resistant psychotic patients ([@B44]). In three of the four studies, the severity of psychotic phenomena decreased. The other studies included patients with BPD without distinctions for psychotic features. Of the 21 studies investigating the efficacy of antipsychotic medication, nine were RCTs with 215 patients in the active condition and 205 in the placebo condition ([@B34]--[@B42]). In three of these studies the severity of psychotic symptoms was explored, but no decrease in severity was found in any of them. Paranoid symptoms diminished in six out of nine studies; the remaining 12 were open-label, naturalistic, or case studies, with a total of 152 patients. After treatment with antipsychotic medication, the severity of psychotic symptoms was reduced in all six studies that assessed this, and the severity of paranoid symptoms was reduced in six of eight studies. The severity of hallucinations was included as an outcome measure in only one study ([@B44]); in that study clozapine reduced the severity of therapy-resistant AVH. No clinical trials were found in which the severity of AVH was used as an outcome measure. However, AVH subsided after treatment with antipsychotics in two patients described in a case report ([@B27]). The antipsychotic dosages used in seven studies were 1,3 up to 5 times lower compared to those regularly used for patients with psychotic disorders ([@B34], [@B35], [@B37], [@B38], [@B42], [@B43], [@B45]), while the other studies applied regular dosages. However, antipsychotics were effective in reducing psychotic symptoms, even at low dosages. In one study, the effect of quetiapine was explored in patients with BPD, drug-induced psychosis, and schizophrenia ([@B51]). At the end of that study, the mean scores of each rating scale were significantly lower in the population as a whole, and also within each diagnostic group. The percentage improvement was significantly greater in patients with drug-induced psychosis than in those with schizophrenia or BPD. The mean weighted percentage of dropouts in patients using typical antipsychotics was 36 and 43% for atypical antipsychotics. Among the atypical antipsychotics, side effects occurred with the following mean weighted percentages: 42% for sedation, 78% for drooling, 44% for weight gain, 29% for nausea, 22% for dizziness, 11% for tremor, 11% for anxiety, 18% for irritability, 63% for increased appetite, 38% for dry mouth, 15% for akathisia, 13% for confusion, 14% for insomnia, 11% for headache, and 5% for other side effects. The mean weight gain associated with the use of olanzapine ranged from 1.3 to 4.5 kg. The side effects of the typical antipsychotic thioridazine (the only publication of typical antipsychotics reporting side effects) were dry mouth (58%), dizziness (50%), sedation (42%), weight gain (33%), constipation 17%, and akathisia (8%).

Discussion {#s4}
==========

This systematic review presents an update on auditory verbal hallucinations (AVH) among patients with borderline personality disorder (BPD), with a special focus on the efficacy of treatments for psychotic symptoms. It was found that AVH in BPD are generally severe and in need of effective treatment. Auditory hallucinations, including AVH, were reported in 27% of inpatients with BPD. AVH were experienced in 25% of all patients and in 24% of the outpatients. These results are positioned between the prevalence rates for AVH in the general population, i.e., 9% ([@B4], [@B7]), and in schizophrenia \[70--80%, ([@B10])\]. Of all patients with BPD and AVH, 78% perceived their AVH at least once per day and the ensuing distress was rated as high. The duration of experiencing AVH ranged from several days to many years. These findings are in contrast with the older literature which characterizes AVH in the context of BPD as mild and transient ([@B20], [@B57]). Furthermore, the phenomenological characteristics of AVH in patients with BPD do not differ from those in schizophrenia, and the ensuing distress might be even higher. Patients with BPD tend to experience their voices as malevolent and omnipotent, and higher in social rank than themselves. These findings are in line with those for schizophrenia ([@B31], [@B58]). The majority of BPD patients with AVH experienced hallucinations in at least one other sensory modality, with visual hallucinations being the most prominent. Scores for delusions were positive in 44% of the patients, and for suspiciousness and ideas of persecution in 33%. However, compared to patients diagnosed with schizophrenia, the overall scores for positive and negative symptoms were lower in patients with BPD ([@B10], [@B33]).

The prevalence rate for imperative hallucinations of 56% is in line with the findings that the presence of AVH in the context of BPD was associated with an increase in the incidence of suicidal plans and attempts, as well as with the number of hospitalizations. The same applies for suicidality in patients with AVH in schizophrenia spectrum disorders ([@B59], [@B60]). Comorbidity (e.g., with mood disorders and substance use disorders) has sometimes been held responsible for the occurrence of AVH in patients with BPD ([@B3]). In two studies the relationship of AVH with comorbidity and childhood trauma was investigated. In the present BPD group, PTSD was the only comorbid disorder associated with AVH. Comorbid dissociative disorders were more prevalent among patients with AVH and BPD compared to those with schizophrenia ([@B33]). The number of patients with childhood abuse was higher in BPD patients with AVH than in those without AVH. These findings are similar to those for childhood abuse reported for psychotic disorders ([@B61]).

Psychotherapies, notably dialectical behavior therapy, are effective for BPD core pathology and associated general psychopathology ([@B62], [@B63]). Of the 22 studies that assessed the efficacy of treatments for psychotic features in patients with BPD, only one assessed the efficacy of a first-episode specialty program, and none evaluated the efficacy of CBT, tDCS or rTMS for AVH. In most studies the severity of psychotic symptoms and paranoid delusions decreased with the use of antipsychotics; however, there were considerable dropouts and side effects (the most common being drooling, increased appetite, sedation, dry mouth, and weight gain).

Although the number of studies was low, these findings indicate that antipsychotics tend to have a beneficial effect on psychotic symptoms experienced in the context of BPD. Moreover, it should be noted that, since the majority of studies (i.e., 17 of 21) included patients with *and* without psychotic symptoms, the antipsychotics would probably have shown greater benefit if patients with psychotic symptoms *alone* would have been included. Furthermore, the effects of antipsychotics are expected to increase with higher dosages. These results are in line with other meta-analyses which found small to moderate effect sizes for antipsychotics in the treatment of psychotic symptoms in patients with BPD ([@B64]--[@B66]). In one study, the effects of antipsychotics did not differ from those in patients with schizophrenia ([@B51]). Finally, patients with BPD and psychotic disorders might benefit from a combination of a specialist first-episode treatment plus specialist early intervention for borderline personality, as investigated by Gleeson et al. ([@B54]).

Implications for clinical practice and future research
------------------------------------------------------

The findings presented in this systematic review have four main implications. Firstly, AVH among patients with BPD are common. Since they are associated with high levels of distress and their consequences can be severe, these patients deserve appropriate treatment for their AVH. This is in contrast with the older literature, where psychotic symptoms are sometimes dismissed as "psychotic-like" symptoms or "pseudohallucinations" and, therefore, do not get the attention they deserve ([@B30]). Secondly, our findings indicate that the psychotic symptoms experienced by patients with BPD resemble those experienced by patients diagnosed with schizophrenia (although delusions, negative symptoms and disorganization are less common). Therefore, AVH as experienced in the context of BPD appear to lie on a continuum with those in individuals without a psychiatric diagnosis, and those with schizophrenia. This is in line with the original meaning of the term "borderline disorder" which was introduced to designate a condition in the borderline area between neurotic and psychotic disorders, with the possibility of occasional transgressions of the border in either direction ([@B67]). Although even BPD patients with persistent hallucinations are rarely diagnosed with a DSM-5 diagnosis of schizophrenia spectrum disorder ([@B30]), we argue that, in specific cases, it would be better to diagnose both disorders and offer treatment accordingly, especially when the distress caused by those hallucinations is high. Thirdly, our findings also imply that patients with BPD and psychotic symptoms are likely to benefit from antipsychotic medication. When side effects are mild or absent, there is no reason to withhold these patients from higher dosages if lower dosages fail to yield adequate effects. Fourth and finally, patients with BPD and AVH might benefit from other treatments for psychotic disorders, such as CBT and non-invasive brain-stimulation techniques ([@B1], [@B5]). In CBT, control over symptoms and problems can be obtained with the aid of a personalized case formulation. Of special interest is the frequent presence of command hallucinations in BPD, which may lead to suicidal behavior ([@B68]). These patients might benefit from CBT specifically designed for the treatment of command hallucinations ([@B69]). rTMS and tDCS are thought to normalize increased brain activity with a rapidly changing magnetic field, and a low-intensity current, respectively. Patients undergo these treatment under full consciousness. If applied in conformance with international safety guidelines. The modalities rTMS and tDCS are safe and their side effects (if present) are temporary and mild. Moreover, non-invasive brain stimulation is beneficial in patients with psychotic features and AVH ([@B6], [@B8], [@B70]--[@B72]).

Limitations
-----------

An important limitation of the present study is the relatively low number of original studies and numbers of patients included per study. Moreover, the use of differing assessment methods and questionnaires in the original studies makes it difficult to directly compare their findings, and is therefore a minor limitation.

Conclusions {#s5}
===========

AVH have a mean weighted prevalence of 26% in patients with BPD. They tend to be experienced as severe and their phenomenological characteristics do not differ from those in patients diagnosed with schizophrenia. These findings emphasis the need for proper diagnosis and appropriate treatment. There is some evidence that antipsychotics are effective in the treatment of psychotic symptoms in patients with BPD. In addition, these patients might benefit from other treatments for psychosis, such as CBT and non-invasive brain stimulation. Future studies should be directed at assessing the effects of such treatment strategies for this underserved subpopulation.
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